Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: MK-0777 for the Treatment of Cognitive Impairments in Patients With Schizophrenia
Brief Summary: Patients with schizophrenia are characterized by a broad range of neurocognitive abnormalities. These include impairments in attention, including abnormalities in sensory gating; executive function; visual and verbal learning and memory; working memory; processing speed; and social cognition (Nuechterlein et al, 2004). These impairments are major determinants of poor functional outcome in patients with schizophrenia (Green, 1996; Green et al, 2004). Conventional antipsychotics have limited effects on these impairments. Second generation antipsychotics may have modest benefits for cognitive function, but whether this represents a direct cognitive enhancing effect has not been established. Regardless, patients continue to exhibit pronounced cognitive impairments despite adequate second generation antipsychotic treatment. Adjunctive pharmacotherapy may offer a viable approach for the treatment of cognitive impairments. Adjunctive agents can be used to modulate specific neurotransmitter systems that are hypothesized to be involved in the pharmacology of cognitive functions.

The standard of care for schizophrenia is antipsychotic medications to treat psychotic symptoms. However, cognitive impairments remain and these impairments have been found to be significantly associated with the poor psychosocial function observed in patients with schizophrenia. There is a considerable preclinical rationale for the use of drugs that act at the Gamma-amino-buyric acid (GABA) α2 subunit as adjunctive treatments to target cognitive impairments. MK-0777 GEM (Merck-0777 Gel Extrusion Module) formulation provides an opportunity to directly test this mechanism.

The purpose of the proposed study is to examine the efficacy and safety of two doses of MK (Merck) -0777 GEM, 3 mg BID (twice daily) and 8 mg BID (twice daily), in the treatment of cognitive impairments in patients with schizophrenia. Secondary goals are to determine whether MK-0777 has beneficial effects on measures of functional capacity and patient self-report of cognitive function.


Options:
A: Arm Label: LY2140023; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: Olanzapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: olanzapine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: LY2140023; Assigned to Arm(s): LY2140023 | Intervention Type: DRUG; Name: olanzapine; Assigned to Arm(s): Olanzapine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: MK-0777 8 mg; Type: EXPERIMENTAL; Interventions: Drug: MK-0777 | Arm Label: MK-0777 3 mg; Type: EXPERIMENTAL; Interventions: Drug: MK-0777 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: MK-0777; Assigned to Arm(s): MK-0777 8 mg | Intervention Type: DRUG; Name: MK-0777; Assigned to Arm(s): MK-0777 3 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 5; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 6; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine, Drug: Placebo | Intervention Type: DRUG; Name: LY2140023; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: LY2140023; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: LY2140023; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: LY2140023; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): 6 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 6 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 5
D: Intervention Type: DRUG; Name: paliperidone palmitate; Assigned to Arm(s): N/A

Answer: B